Ignite Creation Date:
2025-12-24 @ 11:42 PM
Ignite Modification Date:
2025-12-25 @ 9:33 PM
Study NCT ID:
NCT05356351
Status:
NOT_YET_RECRUITING
Last Update Posted:
2022-05-02
First Post:
2022-04-18
Is NOT Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
An Open-label, Single-arm, Multicenter Phase II Clinical Study： Evaluating RC48-ADC Combined With Triplizumab in the Neoadjuvant Treatment of Her2-positive Muscle-invasive Bladder Cancer
Sponsor:
Tianjin Medical University Cancer Institute and Hospital
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2022-05-01
Start Date Type:
ESTIMATED
Primary Completion Date:
2023-07-01
Primary Completion Date Type:
ESTIMATED
Completion Date:
2027-07-30
Completion Date Type:
ESTIMATED
First Submit Date:
2022-04-18
First Submit QC Date:
None
Study First Post Date:
2022-05-02
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2022-04-29
Last Update Post Date:
2022-05-02
Last Update Post Date Type:
ACTUAL